Literature DB >> 27226567

Xyloside-primed Chondroitin Sulfate/Dermatan Sulfate from Breast Carcinoma Cells with a Defined Disaccharide Composition Has Cytotoxic Effects in Vitro.

Andrea Persson1, Emil Tykesson2, Gunilla Westergren-Thorsson2, Anders Malmström2, Ulf Ellervik3, Katrin Mani2.   

Abstract

We previously reported that the xyloside 2-(6-hydroxynaphthyl) β-d-xylopyranoside (XylNapOH), in contrast to 2-naphthyl β-d-xylopyranoside (XylNap), specifically reduces tumor growth both in vitro and in vivo Although there are indications that this could be mediated by the xyloside-primed glycosaminoglycans (GAGs) and that these differ in composition depending on xyloside and cell type, detailed knowledge regarding a structure-function relationship is lacking. In this study we isolated XylNapOH- and XylNap-primed GAGs from a breast carcinoma cell line, HCC70, and a breast fibroblast cell line, CCD-1095Sk, and demonstrated that both XylNapOH- and XylNap-primed chondroitin sulfate/dermatan sulfate GAGs derived from HCC70 cells had a cytotoxic effect on HCC70 cells and CCD-1095Sk cells. The cytotoxic effect appeared to be mediated by induction of apoptosis and was inhibited in a concentration-dependent manner by the XylNap-primed heparan sulfate GAGs. In contrast, neither the chondroitin sulfate/dermatan sulfate nor the heparan sulfate derived from CCD-1095Sk cells primed on XylNapOH or XylNap had any effect on the growth of HCC70 cells or CCD-105Sk cells. These observations were related to the disaccharide composition of the XylNapOH- and XylNap-primed GAGs, which differed between the two cell lines but was similar when the GAGs were derived from the same cell line. To our knowledge this is the first report on cytotoxic effects mediated by chondroitin sulfate/dermatan sulfate.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  cancer; chondroitin sulfate; dermatan sulfate; disaccharide fingerprint; glycosaminoglycan; heparan sulfate; high-performance liquid chromatography (HPLC); structure-function; xyloside

Mesh:

Substances:

Year:  2016        PMID: 27226567      PMCID: PMC4938203          DOI: 10.1074/jbc.M116.716829

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

2.  Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis.

Authors:  Dongfang Liu; Zachary Shriver; Ganesh Venkataraman; Yosuf El Shabrawi; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

3.  Proliferation of cultured fibroblasts is inhibited by L-iduronate-containing glycosaminoglycans.

Authors:  G Westergren-Thorsson; P O Onnervik; L A Fransson; A Malmström
Journal:  J Cell Physiol       Date:  1991-06       Impact factor: 6.384

4.  A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis.

Authors:  J R Toomey; M A Abboud; R E Valocik; P F Koster; C L Burns-Kurtis; K Pillarisetti; T M Danoff; J A Erhardt
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

5.  Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.

Authors:  Mårten Jacobsson; Ulf Ellervik; Mattias Belting; Katrin Mani
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

6.  Biosynthesis of heparan sulfate on beta-D-xylosides depends on aglycone structure.

Authors:  T A Fritz; F N Lugemwa; A K Sarkar; J D Esko
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

7.  Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.

Authors:  D R Ferro; A Provasoli; M Ragazzi; B Casu; G Torri; V Bossennec; B Perly; P Sinaÿ; M Petitou; J Choay
Journal:  Carbohydr Res       Date:  1990-01-15       Impact factor: 2.104

8.  Tumor attenuation by 2(6-hydroxynaphthyl)-beta-D-xylopyranoside requires priming of heparan sulfate and nuclear targeting of the products.

Authors:  Katrin Mani; Mattias Belting; Ulf Ellervik; Niklas Falk; Gabriel Svensson; Staffan Sandgren; Fang Cheng; Lars-Ake Fransson
Journal:  Glycobiology       Date:  2004-01-12       Impact factor: 4.313

9.  Effects of cycloheximide, brefeldin A, suramin, heparin and primaquine on proteoglycan and glycosaminoglycan biosynthesis in human embryonic skin fibroblasts.

Authors:  L A Fransson; P Karlsson; A Schmidtchen
Journal:  Biochim Biophys Acta       Date:  1992-11-17

10.  Exogenous addition of a C-xylopyranoside derivative stimulates keratinocyte dermatan sulfate synthesis and promotes migration.

Authors:  Jun Muto; Nandita Natasha Naidu; Kenshi Yamasaki; Nathalie Pineau; Lionel Breton; Richard L Gallo
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

View more
  12 in total

1.  LC-MS/MS characterization of xyloside-primed glycosaminoglycans with cytotoxic properties reveals structural diversity and novel glycan modifications.

Authors:  Andrea Persson; Alejandro Gomez Toledo; Egor Vorontsov; Waqas Nasir; Daniel Willén; Fredrik Noborn; Ulf Ellervik; Katrin Mani; Jonas Nilsson; Göran Larson
Journal:  J Biol Chem       Date:  2018-05-08       Impact factor: 5.157

Review 2.  Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease.

Authors:  Amrita Basu; Neil G Patel; Elijah D Nicholson; Ryan J Weiss
Journal:  Am J Physiol Cell Physiol       Date:  2022-03-16       Impact factor: 5.282

Review 3.  The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer.

Authors:  Adam Pudełko; Grzegorz Wisowski; Krystyna Olczyk; Ewa Maria Koźma
Journal:  FEBS J       Date:  2019-02-05       Impact factor: 5.542

Review 4.  Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Authors:  Giancarlo Ghiselli
Journal:  Medicines (Basel)       Date:  2019-07-29

5.  Glycosaminoglycan Domain Mapping of Cellular Chondroitin/Dermatan Sulfates.

Authors:  Andrea Persson; Egor Vorontsov; Göran Larson; Jonas Nilsson
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

6.  Dermatan Sulfate Affects Breast Cancer Cell Function via the Induction of Necroptosis.

Authors:  Grzegorz Wisowski; Adam Pudełko; Krystyna Olczyk; Monika Paul-Samojedny; Ewa M Koźma
Journal:  Cells       Date:  2022-01-05       Impact factor: 6.600

7.  Site-specific identification of heparan and chondroitin sulfate glycosaminoglycans in hybrid proteoglycans.

Authors:  Fredrik Noborn; Alejandro Gomez Toledo; Anders Green; Waqas Nasir; Carina Sihlbom; Jonas Nilsson; Göran Larson
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

8.  A glycan-based approach to therapeutic angiogenesis.

Authors:  Jie Shi Chua; Vy M Tran; Mausam Kalita; Maritza V Quintero; Orlando Antelope; Geethu Muruganandam; Yukio Saijoh; Balagurunathan Kuberan
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

9.  Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.

Authors:  Eugeni Entchev; Ingrid Jantzen; Philippe Masson; Stephanie Bocart; Bruno Bournique; Jean-Michel Luccarini; Andre Bouchot; Olivier Lacombe; Jean-Louis Junien; Pierre Broqua; Mireille Tallandier
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

10.  Domain Mapping of Chondroitin/Dermatan Sulfate Glycosaminoglycans Enables Structural Characterization of Proteoglycans.

Authors:  Andrea Persson; Mahnaz Nikpour; Egor Vorontsov; Jonas Nilsson; Göran Larson
Journal:  Mol Cell Proteomics       Date:  2021-03-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.